Drugs that contain Diclofenac Potassium
1. Cambia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7482377 | ASSERTIO | Pharmaceutical compositions and methods of treatment based on diclofenac |
May, 2017
(6 years ago) | |
| US8097651 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| US7759394 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6974595 | ASSERTIO | Pharmaceutical compositions based on Diclofenae |
May, 2017
(6 years ago) | |
| US9827197 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| US8927604 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2012 |
Market Authorisation Date: 17 June, 2009
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: FOR SOLUTION;ORAL
How can I launch a generic of CAMBIA before it's drug patent expiration?
More Information on Dosage
CAMBIA family patents
2. Zipsor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6287594 | ASSERTIO | Oral liquid compositions |
Jan, 2019
(5 years ago) | |
| US6365180 | ASSERTIO | Oral liquid compositions |
Jul, 2019
(4 years ago) | |
| US7662858 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US7939518 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US8110606 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US9561200 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US8623920 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US7884095 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 25, 2024 |
| New Dosage Form(NDF) | Jun 16, 2012 |
Market Authorisation Date: 16 June, 2009
Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain
Dosage: CAPSULE;ORAL
How can I launch a generic of ZIPSOR before it's drug patent expiration?
More Information on Dosage
ZIPSOR family patents